Genetic and imaging strategies in obsessive-compulsive disorder: potential implications for treatment development.
In recent years, advances in brain research have resulted in a striking strategic shift in studies designed to develop new, effective treatments for neuropsychiatric disorders. This involves a multidisciplinary approach with recursive interactions among respective disciplines with the ultimate goal of contributing to treatment development. In this review we focus on treatment implications of brain imaging and molecular and pharmacogenetic studies in obsessive-compulsive disorder. Translational components of this research are addressed, including the potential for integrating advances in brain imaging and molecular and pharmacogenetic assessments as they may potentially relate to neurodiagnostic assessment and treatment development. Studies of putative susceptibility alleles in obsessive-compulsive disorder involving the serotonergic, glutamatergic, and dopaminergic systems may provide a focus for these divergent approaches. Taken together, neuroimaging and genetic methods may ultimately lead to a mechanistic understanding of the pathogenesis and maintenance of neuropsychiatric disorders such as obsessive-compulsive disorder that may, in turn, result in the development of new neurodiagnostic and treatment approaches.
Rosenberg
D R
DR
Departments of Psychiatry & Behavioral Neurosciences and Pediatrics, Wayne State University, (DRR), Detroit, Michigan 48201, USA.
Hanna
G L
GL
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D001923:Brain Chemistry; D002648:Child; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008967:Molecular Biology; D009154:Mutation; D009771:Obsessive-Compulsive Disorder / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics*; D010641:Phenotype; D011110:Polymorphism, Genetic; D011877:Radionuclide Imaging